Lapatinib in Postmenopausal Women with Hormone Receptor-Positive, HER2-Positive Metastatic Breast Cancer Profile Report

被引：0
|
作者：
Curran, Monique P. [1 ]
机构：
[1] Adis, Auckland 075, New Zealand
来源：
BIODRUGS | 2011年 / 25卷 / 01期
关键词：
THERAPY;
D O I：
10.2165/11207270-000000000-00000
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
[No abstract available]
引用
收藏
页码：53 / 54
页数：2
相关论文
共 50 条
  • [1] Lapatinib In Postmenopausal Women with Hormone Receptor-Positive, HER2-Positive Metastatic Breast Cancer
    Curran, Monique P.
    DRUGS, 2010, 70 (11) : 1411 - 1422
  • [2] Lapatinib in Postmenopausal Women with Hormone Receptor-Positive, HER2-Positive Metastatic Breast CancerProfile Report
    Monique P. Curran
    BioDrugs, 2011, 25 : 53 - 54
  • [3] LapatinibIn Postmenopausal Women with Hormone Receptor-Positive, HER2-Positive Metastatic Breast Cancer
    Monique P. Curran
    Drugs, 2010, 70 : 1411 - 1422
  • [4] The evolving landscape of metastatic HER2-positive, hormone receptor-positive Breast Cancer
    Bielo, Luca Boscolo
    Trapani, Dario
    Nicolo, Eleonora
    Valenza, Carmine
    Guidi, Lorenzo
    Belli, Carmen
    Kotteas, Elias
    Marra, Antonio
    Prat, Aleix
    Fusco, Nicola
    Criscitiello, Carmen
    Burstein, Harold J.
    Curigliano, Giuseppe
    CANCER TREATMENT REVIEWS, 2024, 128
  • [5] Cost-effectiveness of lapatinib plus letrozole in HER2-positive, hormone receptor-positive metastatic breast cancer in Canada
    Delea, T. E.
    Amdahl, J.
    Chit, A.
    Amonkar, M. M.
    CURRENT ONCOLOGY, 2013, 20 (05) : E371 - E387
  • [6] Clinical utility of the combination of lapatinib and letrozole in the management of hormone receptor-positive and HER2-positive advanced breast cancer
    Merriam, Priscilla
    Sikov, William M.
    BREAST CANCER-TARGETS AND THERAPY, 2011, 3 : 139 - 150
  • [7] Prognostic significance of estrogen receptor in hormone receptor-positive and HER2-positive breast cancer
    Hikichi, M.
    Ushimado, K.
    Ri, Y.
    Kobayashi, N.
    Utsumi, T.
    BREAST, 2017, 32 : S94 - S95
  • [8] Significant response to the combination of pyrotinib and letrozole in a patient with metastatic HER2-positive and hormone receptor-positive breast cancer: a case report
    Li, Jing
    Shui, Zhengrong
    Ouyang, Quchang
    ANNALS OF PALLIATIVE MEDICINE, 2021, 10 (09) : 10124 - 10129
  • [9] HER2-positive and Hormone Receptor-positive Metastatic Breast Cancer Significant Survival Advantage with Kadcyla in the Second Line
    不详
    ONCOLOGY RESEARCH AND TREATMENT, 2018, 41 (06) : 418 - 418
  • [10] Lapatinib in HER2-positive breast cancer
    Nelson, Roxanne
    LANCET ONCOLOGY, 2018, 19 (01): : 22 - 22
12345